tradingkey.logo

Assertio Holdings Inc

ASRT
View Detailed Chart
0.750USD
+0.025+3.45%
Close 11/05, 16:00ETQuotes delayed by 15 min
72.18MMarket Cap
LossP/E TTM

Assertio Holdings Inc

0.750
+0.025+3.45%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.45%

5 Days

-2.80%

1 Month

-17.52%

6 Months

+23.45%

Year to Date

-13.88%

1 Year

-26.45%

View Detailed Chart

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Assertio Holdings Inc's Score

Industry at a Glance

Industry Ranking
111 / 159
Overall Ranking
290 / 4616
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
2.688
Target Price
+270.59%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Assertio Holdings Inc Highlights

StrengthsRisks
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Fairly Valued
The company’s latest PE is -1.66, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 25.82M shares, decreasing 46.89% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 2.82M shares of this stock.

Assertio Holdings Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Assertio Holdings Inc Info

Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Ticker SymbolASRT
CompanyAssertio Holdings Inc
CEOMr. Brendan P. O'Grady
Websitehttps://www.assertiotx.com/
KeyAI